Cargando…

Identifies KCTD5 as a novel cancer biomarker associated with programmed cell death and chemotherapy drug sensitivity

BACKGROUND: More and more studies have demonstrated that potassium channel tetramerization domain-containing 5 (KCTD5) plays an important role in the development of cancer, but there is a lack of comprehensive research on the biological function of this protein in pan-cancer. This study systematical...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Yuan-Xiang, Yan, Jian-Hua, Liu, Wen, Deng, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10163697/
https://www.ncbi.nlm.nih.gov/pubmed/37149576
http://dx.doi.org/10.1186/s12885-023-10895-2
_version_ 1785037936760193024
author Shi, Yuan-Xiang
Yan, Jian-Hua
Liu, Wen
Deng, Jun
author_facet Shi, Yuan-Xiang
Yan, Jian-Hua
Liu, Wen
Deng, Jun
author_sort Shi, Yuan-Xiang
collection PubMed
description BACKGROUND: More and more studies have demonstrated that potassium channel tetramerization domain-containing 5 (KCTD5) plays an important role in the development of cancer, but there is a lack of comprehensive research on the biological function of this protein in pan-cancer. This study systematically analyzed the expression landscape of KCTD5 in terms of its correlations with tumor prognosis, the immune microenvironment, programmed cell death, and drug sensitivity. METHODS: We investigated a number of databases, including TCGA, GEPIA2, HPA, TISIDB, PrognoScan, GSCA, CellMiner, and TIMER2.0. The study evaluated the expression of KCTD5 in human tumors, as well as its prognostic value and its association with genomic alterations, the immune microenvironment, tumor-associated fibroblasts, functional enrichment analysis, and anticancer drug sensitivity. Real-time quantitative PCR and flow cytometry analysis were performed to determine the biological functions of KCTD5 in lung adenocarcinoma cells. RESULTS: The results indicated that KCTD5 is highly expressed in most cancers and that its expression is significantly correlated with tumor prognosis. Moreover, KCTD5 expression was related to the immune microenvironment, infiltration by cancer-associated fibroblasts, and the expression of immune-related genes. Functional enrichment analysis revealed that KCTD5 is associated with apoptosis, necroptosis, and other types of programmed cell death. In vitro experiments showed that knockdown of KCTD5 promoted apoptosis of A549 cells. Correlation analysis confirmed that KCTD5 was positively correlated with the expression of the anti-apoptotic genes Bcl-xL and Mcl-1. Additionally, KCTD5 was significantly associated with sensitivity to multiple antitumor drugs. CONCLUSION: Our results suggest that KCTD5 is a potential molecular biomarker that can be used to predict patient prognosis, immunoreactions and drug sensitivity in pan-cancer. KCTD5 plays an important role in regulating programmed cell death, especially apoptosis. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-023-10895-2.
format Online
Article
Text
id pubmed-10163697
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-101636972023-05-07 Identifies KCTD5 as a novel cancer biomarker associated with programmed cell death and chemotherapy drug sensitivity Shi, Yuan-Xiang Yan, Jian-Hua Liu, Wen Deng, Jun BMC Cancer Research BACKGROUND: More and more studies have demonstrated that potassium channel tetramerization domain-containing 5 (KCTD5) plays an important role in the development of cancer, but there is a lack of comprehensive research on the biological function of this protein in pan-cancer. This study systematically analyzed the expression landscape of KCTD5 in terms of its correlations with tumor prognosis, the immune microenvironment, programmed cell death, and drug sensitivity. METHODS: We investigated a number of databases, including TCGA, GEPIA2, HPA, TISIDB, PrognoScan, GSCA, CellMiner, and TIMER2.0. The study evaluated the expression of KCTD5 in human tumors, as well as its prognostic value and its association with genomic alterations, the immune microenvironment, tumor-associated fibroblasts, functional enrichment analysis, and anticancer drug sensitivity. Real-time quantitative PCR and flow cytometry analysis were performed to determine the biological functions of KCTD5 in lung adenocarcinoma cells. RESULTS: The results indicated that KCTD5 is highly expressed in most cancers and that its expression is significantly correlated with tumor prognosis. Moreover, KCTD5 expression was related to the immune microenvironment, infiltration by cancer-associated fibroblasts, and the expression of immune-related genes. Functional enrichment analysis revealed that KCTD5 is associated with apoptosis, necroptosis, and other types of programmed cell death. In vitro experiments showed that knockdown of KCTD5 promoted apoptosis of A549 cells. Correlation analysis confirmed that KCTD5 was positively correlated with the expression of the anti-apoptotic genes Bcl-xL and Mcl-1. Additionally, KCTD5 was significantly associated with sensitivity to multiple antitumor drugs. CONCLUSION: Our results suggest that KCTD5 is a potential molecular biomarker that can be used to predict patient prognosis, immunoreactions and drug sensitivity in pan-cancer. KCTD5 plays an important role in regulating programmed cell death, especially apoptosis. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-023-10895-2. BioMed Central 2023-05-06 /pmc/articles/PMC10163697/ /pubmed/37149576 http://dx.doi.org/10.1186/s12885-023-10895-2 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Shi, Yuan-Xiang
Yan, Jian-Hua
Liu, Wen
Deng, Jun
Identifies KCTD5 as a novel cancer biomarker associated with programmed cell death and chemotherapy drug sensitivity
title Identifies KCTD5 as a novel cancer biomarker associated with programmed cell death and chemotherapy drug sensitivity
title_full Identifies KCTD5 as a novel cancer biomarker associated with programmed cell death and chemotherapy drug sensitivity
title_fullStr Identifies KCTD5 as a novel cancer biomarker associated with programmed cell death and chemotherapy drug sensitivity
title_full_unstemmed Identifies KCTD5 as a novel cancer biomarker associated with programmed cell death and chemotherapy drug sensitivity
title_short Identifies KCTD5 as a novel cancer biomarker associated with programmed cell death and chemotherapy drug sensitivity
title_sort identifies kctd5 as a novel cancer biomarker associated with programmed cell death and chemotherapy drug sensitivity
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10163697/
https://www.ncbi.nlm.nih.gov/pubmed/37149576
http://dx.doi.org/10.1186/s12885-023-10895-2
work_keys_str_mv AT shiyuanxiang identifieskctd5asanovelcancerbiomarkerassociatedwithprogrammedcelldeathandchemotherapydrugsensitivity
AT yanjianhua identifieskctd5asanovelcancerbiomarkerassociatedwithprogrammedcelldeathandchemotherapydrugsensitivity
AT liuwen identifieskctd5asanovelcancerbiomarkerassociatedwithprogrammedcelldeathandchemotherapydrugsensitivity
AT dengjun identifieskctd5asanovelcancerbiomarkerassociatedwithprogrammedcelldeathandchemotherapydrugsensitivity